KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Operating Income (2016 - 2025)

Historic Operating Income for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $3.3 billion.

  • Gilead Sciences' Operating Income rose 27466.22% to $3.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 billion, marking a year-over-year increase of 117615.57%. This contributed to the annual value of $1.7 billion for FY2024, which is 7814.6% down from last year.
  • According to the latest figures from Q3 2025, Gilead Sciences' Operating Income is $3.3 billion, which was up 27466.22% from $2.5 billion recorded in Q2 2025.
  • Gilead Sciences' Operating Income's 5-year high stood at $3.8 billion during Q3 2021, with a 5-year trough of -$4.3 billion in Q1 2024.
  • Over the past 5 years, Gilead Sciences' median Operating Income value was $2.2 billion (recorded in 2021), while the average stood at $1.8 billion.
  • Per our database at Business Quant, Gilead Sciences' Operating Income skyrocketed by 76548.22% in 2023 and then crashed by 35348.97% in 2024.
  • Quarter analysis of 5 years shows Gilead Sciences' Operating Income stood at $940.0 million in 2021, then skyrocketed by 141.17% to $2.3 billion in 2022, then decreased by 28.89% to $1.6 billion in 2023, then soared by 52.11% to $2.5 billion in 2024, then surged by 35.69% to $3.3 billion in 2025.
  • Its Operating Income was $3.3 billion in Q3 2025, compared to $2.5 billion in Q2 2025 and $2.2 billion in Q1 2025.